by Elena Iemma | Jan 12, 2026 | Blog
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
by Adam | Mar 20, 2020 | News
Providence biotech company working to create coronavirus vaccine by TAMARA SACHARCZYK, NBC 10 NEWS Wednesday, March 18th 2020 Find the full story here EpiVax in Providence. (WJAR) A team of local scientists are on the front lines of a global pandemic as they race...
by Annie De Groot | Jan 29, 2020 | Events
Dr. Anne De Groot will be in Ventura Beach, CA for the Gordon Research Center: Advancing Peptides as Tools, Materials and Therapeutics Conference. While there, Annie will be giving a talk on “Immunogenicity of Peptide Drugs and Their Impurities: Taspoglutide...
by Annie De Groot | Jul 14, 2019 | Events
11th Annual Protein & Antibody Engineering Summit (PEGS) Europe Monday, November 18th – Friday, November 22nd Lisbon Congress Center Lisbon, Portugal Our European Representative, Paul Von Hoegen, and Business Development Associate, Sarah Moniz, will be...
